JP2018504907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504907A5 JP2018504907A5 JP2017539428A JP2017539428A JP2018504907A5 JP 2018504907 A5 JP2018504907 A5 JP 2018504907A5 JP 2017539428 A JP2017539428 A JP 2017539428A JP 2017539428 A JP2017539428 A JP 2017539428A JP 2018504907 A5 JP2018504907 A5 JP 2018504907A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- sequence
- seq
- amino acid
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110071P | 2015-01-30 | 2015-01-30 | |
| US62/110,071 | 2015-01-30 | ||
| US201562258082P | 2015-11-20 | 2015-11-20 | |
| US62/258,082 | 2015-11-20 | ||
| PCT/US2016/015720 WO2016123521A2 (en) | 2015-01-30 | 2016-01-29 | Fcrn antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021002601A Division JP7224382B2 (ja) | 2015-01-30 | 2021-01-12 | ＦｃＲｎ抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504907A JP2018504907A (ja) | 2018-02-22 |
| JP2018504907A5 true JP2018504907A5 (OSRAM) | 2019-03-14 |
| JP6853178B2 JP6853178B2 (ja) | 2021-03-31 |
Family
ID=56544538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539428A Active JP6853178B2 (ja) | 2015-01-30 | 2016-01-29 | ＦｃＲｎ抗体およびその使用方法 |
| JP2021002601A Active JP7224382B2 (ja) | 2015-01-30 | 2021-01-12 | ＦｃＲｎ抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021002601A Active JP7224382B2 (ja) | 2015-01-30 | 2021-01-12 | ＦｃＲｎ抗体およびその使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10676526B2 (OSRAM) |
| EP (2) | EP4286011A3 (OSRAM) |
| JP (2) | JP6853178B2 (OSRAM) |
| KR (3) | KR102792441B1 (OSRAM) |
| CN (13) | CN118562003A (OSRAM) |
| AU (2) | AU2016211280B2 (OSRAM) |
| CA (1) | CA2972822A1 (OSRAM) |
| DK (1) | DK3250610T3 (OSRAM) |
| ES (1) | ES2962824T3 (OSRAM) |
| FI (1) | FI3250610T3 (OSRAM) |
| HR (1) | HRP20231399T1 (OSRAM) |
| HU (1) | HUE063778T2 (OSRAM) |
| IL (1) | IL252837B (OSRAM) |
| LT (1) | LT3250610T (OSRAM) |
| NZ (1) | NZ772383A (OSRAM) |
| PL (1) | PL3250610T3 (OSRAM) |
| PT (1) | PT3250610T (OSRAM) |
| RS (1) | RS64768B1 (OSRAM) |
| SG (2) | SG10202007232WA (OSRAM) |
| SI (1) | SI3250610T1 (OSRAM) |
| SM (1) | SMT202300365T1 (OSRAM) |
| WO (1) | WO2016123521A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6554473B2 (ja) | 2013-12-24 | 2019-07-31 | アルゲン−エックス ビーブイビーエー | ＦｃＲｎアンタゴニスト及び使用方法 |
| EP3155013B1 (en) * | 2014-06-12 | 2019-03-27 | F. Hoffmann-La Roche AG | Method for selecting antibodies with modified fcrn interaction |
| SG10202007232WA (en) * | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| CA3032415A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| RU2020100880A (ru) * | 2017-06-15 | 2021-07-15 | Юсб Биофарма Срл | Способ лечения иммунной тромбоцитопении |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| AU2018386193B2 (en) * | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| CA3106669A1 (en) * | 2018-07-20 | 2020-01-30 | Momenta Pharmaceuticals, Inc. | Compositions of fcrn antibodies and methods of use thereof |
| EP3823978A4 (en) * | 2018-07-20 | 2022-12-14 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
| MX2021004351A (es) | 2018-10-16 | 2021-05-31 | UCB Biopharma SRL | Metodo para el tratamiento de miastenia grave. |
| JP7565951B2 (ja) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
| JP2022542430A (ja) * | 2019-08-01 | 2022-10-03 | ヤンセン バイオテツク，インコーポレーテツド | Ｆｃｒｎ抗体およびその使用の方法 |
| WO2021101975A1 (en) * | 2019-11-19 | 2021-05-27 | Immunovant Sciences Gmbh | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| TW202233236A (zh) * | 2020-11-06 | 2022-09-01 | 美商健生生物科技公司 | Fcrn抗體及其使用方法 |
| US20240081301A1 (en) * | 2021-02-02 | 2024-03-14 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric fcrn |
| WO2023016538A1 (en) * | 2021-08-13 | 2023-02-16 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing fcrn and uses thereof |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| KR20250018382A (ko) | 2022-05-30 | 2025-02-05 | 한올바이오파마주식회사 | 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편 |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
| IL322228A (en) | 2023-02-04 | 2025-09-01 | Momenta Pharmaceuticals Inc | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068259A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| JP2007501847A (ja) * | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| DK1865986T3 (en) | 2005-03-08 | 2016-04-11 | Pfizer Prod Inc | The anti-CTLA-4 antibody compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| CN101421297A (zh) * | 2006-02-17 | 2009-04-29 | 森托尼克斯制药有限公司 | 阻断lgG对FcRn的结合的肽 |
| WO2007104529A2 (en) * | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CA3131470A1 (en) * | 2008-04-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| JP5683581B2 (ja) * | 2009-06-30 | 2015-03-11 | リサーチ ディベロップメント ファウンデーション | 免疫グロブリンＦｃポリペプチド |
| CN103619353B (zh) * | 2011-06-02 | 2016-01-06 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| SG10202007232WA (en) | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| AU2016230827B2 (en) | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| CA3022547A1 (en) | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| CA3032415A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| AU2018386193B2 (en) | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| CA3106669A1 (en) | 2018-07-20 | 2020-01-30 | Momenta Pharmaceuticals, Inc. | Compositions of fcrn antibodies and methods of use thereof |
| EP3823978A4 (en) | 2018-07-20 | 2022-12-14 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
-
2016
- 2016-01-29 SG SG10202007232WA patent/SG10202007232WA/en unknown
- 2016-01-29 CN CN202410661144.5A patent/CN118562003A/zh active Pending
- 2016-01-29 CN CN202410661133.7A patent/CN118667009A/zh active Pending
- 2016-01-29 KR KR1020227045647A patent/KR102792441B1/ko active Active
- 2016-01-29 SM SM20230365T patent/SMT202300365T1/it unknown
- 2016-01-29 DK DK16744204.5T patent/DK3250610T3/da active
- 2016-01-29 AU AU2016211280A patent/AU2016211280B2/en active Active
- 2016-01-29 CN CN202410661136.0A patent/CN118638230A/zh active Pending
- 2016-01-29 CN CN202110605791.0A patent/CN113384693B/zh active Active
- 2016-01-29 US US15/546,870 patent/US10676526B2/en active Active
- 2016-01-29 CN CN202410661142.6A patent/CN118667011A/zh active Pending
- 2016-01-29 PL PL16744204.5T patent/PL3250610T3/pl unknown
- 2016-01-29 CN CN202410661150.0A patent/CN118667014A/zh active Pending
- 2016-01-29 CN CN202410661131.8A patent/CN118638229A/zh active Pending
- 2016-01-29 SG SG11201705475QA patent/SG11201705475QA/en unknown
- 2016-01-29 SI SI201631739T patent/SI3250610T1/sl unknown
- 2016-01-29 HR HRP20231399TT patent/HRP20231399T1/hr unknown
- 2016-01-29 JP JP2017539428A patent/JP6853178B2/ja active Active
- 2016-01-29 EP EP23189767.9A patent/EP4286011A3/en active Pending
- 2016-01-29 ES ES16744204T patent/ES2962824T3/es active Active
- 2016-01-29 KR KR1020257010788A patent/KR20250052465A/ko active Pending
- 2016-01-29 PT PT167442045T patent/PT3250610T/pt unknown
- 2016-01-29 HU HUE16744204A patent/HUE063778T2/hu unknown
- 2016-01-29 CN CN202410661138.XA patent/CN118652337A/zh active Pending
- 2016-01-29 KR KR1020177024165A patent/KR102483016B1/ko active Active
- 2016-01-29 NZ NZ772383A patent/NZ772383A/en unknown
- 2016-01-29 CN CN202410661149.8A patent/CN118667013A/zh active Pending
- 2016-01-29 RS RS20231028A patent/RS64768B1/sr unknown
- 2016-01-29 CN CN201680008485.6A patent/CN107567460B/zh active Active
- 2016-01-29 WO PCT/US2016/015720 patent/WO2016123521A2/en not_active Ceased
- 2016-01-29 CN CN202410661152.XA patent/CN118667015A/zh active Pending
- 2016-01-29 CN CN202410661147.9A patent/CN118667012A/zh active Pending
- 2016-01-29 EP EP16744204.5A patent/EP3250610B1/en active Active
- 2016-01-29 CN CN202410661140.7A patent/CN118667010A/zh active Pending
- 2016-01-29 LT LTEPPCT/US2016/015720T patent/LT3250610T/lt unknown
- 2016-01-29 FI FIEP16744204.5T patent/FI3250610T3/fi active
- 2016-01-29 CA CA2972822A patent/CA2972822A1/en active Pending
-
2017
- 2017-06-11 IL IL252837A patent/IL252837B/en unknown
-
2020
- 2020-03-20 US US16/825,066 patent/US11732047B2/en active Active
-
2021
- 2021-01-12 JP JP2021002601A patent/JP7224382B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201145A patent/AU2022201145B2/en active Active
-
2023
- 2023-07-13 US US18/351,827 patent/US20240158508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504907A5 (OSRAM) | ||
| JP2017176174A5 (OSRAM) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| JP2013539454A5 (OSRAM) | ||
| JP2018537399A5 (OSRAM) | ||
| WO2016054598A3 (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| WO2016191643A3 (en) | Tigit-binding agents and uses thereof | |
| JP2019524645A5 (OSRAM) | ||
| WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
| WO2017178653A3 (en) | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | |
| EA202092435A3 (ru) | Моноклональные антитела против bcma | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| MX2022006461A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
| JP2014012688A5 (OSRAM) | ||
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| PH12020550078A1 (en) | Novel anti-cd3epsilon antibodies | |
| JP2014518898A5 (OSRAM) | ||
| WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| JP2016116527A5 (OSRAM) | ||
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| WO2015200522A3 (en) | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species | |
| JP2021500874A5 (OSRAM) |